Please use this identifier to cite or link to this item:
http://dspace.bits-pilani.ac.in:8080/jspui/handle/123456789/13481
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gaikwad, Anil Bhanudas | - |
dc.date.accessioned | 2023-12-21T06:41:11Z | - |
dc.date.available | 2023-12-21T06:41:11Z | - |
dc.date.issued | 2020-03 | - |
dc.identifier.uri | https://www.tandfonline.com/doi/abs/10.1080/13813455.2020.1745851 | - |
dc.identifier.uri | http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13481 | - |
dc.description.abstract | Liver and kidney are vital organs that maintain homeostasis and injury to either of them triggers pathogenic pathways affecting the other. For example, non-alcoholic fatty liver disease (NAFLD) promotes the progression of chronic kidney disease (CKD), vice versa acute kidney injury (AKI) endorses the induction and progression of liver dysfunction. Progress in clinical and basic research suggest a role of excessive fructose intake, insulin resistance, inflammatory cytokines production, activation of the renin–angiotensin system, redox imbalance, and their impact on epigenetic regulation of gene expression in this context. Recent developments in experimental and clinical research have identified several biochemical and molecular pathways for AKI-liver interaction, including altered liver enzymes profile, metabolic acidosis, oxidative stress, activation of inflammatory and regulated cell death pathways. This review focuses on the current preclinical and clinical findings on kidney–liver crosstalk in NAFLD-CKD and AKI-liver dysfunction settings and highlights potential molecular mechanisms and therapeutic targets. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Taylor & Francis | en_US |
dc.subject | Pharmacy | en_US |
dc.subject | Non-alcoholic fatty liver disease (NAFLD) | en_US |
dc.subject | Chronic kidney diseases (CKD) | en_US |
dc.subject | Crosstalk | en_US |
dc.subject | Acute Kidney Injury (AKI) | en_US |
dc.title | Crosstalk between kidney and liver in non-alcoholic fatty liver disease: mechanisms and therapeutic approaches | en_US |
dc.type | Article | en_US |
Appears in Collections: | Department of Pharmacy |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.